Return to Listing

2 result(s) for Faslodex

PI Name Protocol # Title
Jacqueline Vuky STUDY00015006 A Phase III, Double-Blind Placebo-Controlled, Randomized Study of Taselisib plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive and HER2-Negative Locally Advanced or Metastatic Breast Cancer who have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy.
Kathleen Kemmer STUDY00016379 C31006: An Open-Label Phase 2 Study of MLN0128 (A TORC1/2 Inhibitor) in Combination With Fulvestrant in Women With ER-Positive/HER2-Negative Advanced or Metastatic Breast Cancer That Has Progressed During or After Aromatase Inhibitor Therapy
 

You may also qualify for Phase 1 Program trials.

 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080